127917-66-2
| 中文名称 | 127917-66-2 |
|---|---|
| 中文同义词 | 化合物 T16770;N-(2-氨基乙基)-5-(3-氟苯基)噻唑-4-甲酰胺 盐酸盐 |
| 英文名称 | N-(2-AMINOETHYL)-5-(3-FLUOROPHENYL)-4-THIAZOLECARBOXAMIDE HYDROCHLORIDE |
| 英文同义词 | RO 41-1049 HYDROCHLORIDE;N-(2-AMINOETHYL)-5-(3-FLUOROPHENYL)-4-THIAZOLECARBOXAMIDE HYDROCHLORIDE;Ro 411049 hydrochloride,Ro 41 1049 hydrochloride;N-(2-Aminoethyl)-5-(3-fluorophenyl)thiazole-4-carboxamide hydrochloride |
| CAS号 | 127917-66-2 |
| 分子式 | C12H13ClFN3OS |
| 分子量 | 301.76 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | Mol File |
| 结构式 |  |
127917-66-2 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 可溶于水中 |
| 形态 | 固体 |
| 颜色 | 白色 |
Ro 41-1049 hydrochloride 是一种可逆的并具有选择性的 monoamine oxidase-A (MAO-A) 抑制剂。在人额叶皮层和胎盘的膜制剂中发现了[3H]Ro 41-1049 的高亲和力结合位点的同质群体 (Kd 值分别为 16.5 和 64.4 nM)。
MAO-A
Ro 41-1049 (1-50 mg/kg; intraperitoneal injection; for 3 hours; Sprague-Dawley rats) treatment inhibits dopamine metabolite formation and increases dopamine levels in a dose-dependent fashion. Pretreatment with Ro 41-1049 (20 mg/kg) significantly increases dopamine formation following L-dopa administration (100 mg/kg IP) while decreasing formation of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).
| Animal Model: | Sprague-Dawley rats (200-240 g) |
| Dosage: | 1 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 50 mg/kg |
| Administration: | Intraperitoneal injection; for 3 hours |
| Result: | Inhibited dopamine metabolite formation and increased dopamine levels in a dose-dependent fashion. Pretreatment with the concentration of 20 mg/kg significantly increased dopamine formation following L-dopa administration while decreasing formation of DOPAC and HVA. |
安全信息
| WGK Germany | 3 |
|---|
| 提供商 | 语言 |
|---|---|
|
英文
|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-100027A | 127917-66-2 Ro 41-1049 hydrochloride | 127917-66-2 | 5mg | 500元 |
| 2024/04/30 | HY-100027A | 127917-66-2 Ro 41-1049 hydrochloride | 127917-66-2 | 10mM * 1mLin DMSO | 550元 |